Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Laboratory data in clinical trials: a statistician's perspective

C Chuang-Stein1

  • 1Pharmacia and Upjohn Company, Kalamazoo, Michigan 49001, USA.

Controlled Clinical Trials
|April 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selection bias for treatments with positive Phase 2 results.

Pharmaceutical statistics·2020
Same author

Recent Developments in the Prevention and Treatment of Missing Data.

Therapeutic innovation & regulatory science·2018
Same author

Discounting phase 2 results when planning phase 3 clinical trials.

Pharmaceutical statistics·2012
Same author

The impact and implication of regression to the mean on the design and analysis of medical investigations.

Statistical methods in medical research·1997
Same author

Multiple comparisons procedures for comparing several treatments with a control based on binary data.

Statistics in medicine·1995
Same author

A new proposal for benefit-less-risk analysis in clinical trials.

Controlled clinical trials·1994

Applied statisticians need better understanding of laboratory data interpretation for clinical trial safety evaluations. This paper addresses key issues in analyzing laboratory data to improve patient safety assessments.

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Drug Safety

Background:

  • Laboratory data are crucial indicators of systemic toxicity in clinical trials.
  • Many statisticians lack expertise in interpreting these vital safety indicators.
  • Effective interpretation is essential for assessing overall patient safety during drug development.

Purpose of the Study:

  • To elucidate the purpose of laboratory evaluations in clinical trials.
  • To highlight critical, often overlooked, issues in the analysis of laboratory safety data.
  • To improve the statistical interpretation of laboratory data for enhanced drug safety assessment.

Main Methods:

  • Discussion of the purpose and significance of laboratory data collection.
  • Analysis of common challenges in laboratory data interpretation.

Related Experiment Videos

  • Review of current practices in safety data analysis.

    • Main Results:

    • Identified a gap in statisticians' understanding of laboratory data interpretation.
    • Highlighted issues with reference range utilization.
    • Critiqued the 'one-parameter-at-a-time' analysis approach.
    • Discussed the exploratory nature of safety data analysis.

    Conclusions:

    • Enhanced statistical understanding of laboratory data is vital for accurate patient safety evaluation.
    • Current analytical practices, including reference range use and single-parameter focus, require re-evaluation.
    • Addressing these issues will improve the reliability of safety assessments in clinical trials.